Cargando…

Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use

BACKGROUND: We use a novel, longitudinal approach to describe average time spent in opioid use disorder (OUD) cascade of care stages for people with HIV (PWH) and with OUD, incorporating four definitions of treatment retention. Using this approach, we describe the impact of cocaine or hazardous alco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pytell, Jarratt D., Fojo, Anthony T., Keruly, Jeanne C., Snow, LaQuita N., Falade-Nwulia, Oluwaseun, Moore, Richard D., Chander, Geetanjali, Lesko, Catherine R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474763/ https://www.ncbi.nlm.nih.gov/pubmed/37660116 http://dx.doi.org/10.1186/s13722-023-00408-8

Ejemplares similares

1508. The effects of the COVID-19 pandemic on depression severity and viral load non-suppression among people with HIV accessing care in an urban infectious disease clinic in Baltimore, MD
por: Verinumbe, Tarfa, et al.
Publicado: (2023)

The relationship of alcohol and other drug use during the COVID-19 pandemic among people with or at risk of HIV; A cross-sectional survey of people enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts
por: Pytell, Jarratt D., et al.
Publicado: (2022)

Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum
por: Falade-Nwulia, Oluwaseun, et al.
Publicado: (2019)

COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts
por: Lesko, Catherine R., et al.
Publicado: (2022)

Impact of Co-occurring Drug Use, Hazardous Alcohol Use, and Mental Health Disorders on Drug Use Patterns in People With HIV and Hepatitis C Virus Infection
por: McCormick, Sean, et al.
Publicado: (2021)

“I’m a Survivor”: Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder
por: Pytell, Jarratt D., et al.
Publicado: (2021)

2943. Hazardous Alcohol Use and Direct-acting Antiviral Therapy Initiation Among People Who Inject Drugs with Current Hepatitis C Infection
por: Karimi-Sari, Hamidreza, et al.
Publicado: (2023)

48. Time Between Viral Loads for Suppressed and Non-Suppressed People with HIV During the COVID-19 Pandemic Compared to Pre-Pandemic
por: El-Nahal, Walid, et al.
Publicado: (2021)

Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic()
por: Pytell, Jarratt D., et al.
Publicado: (2021)

The temporal relationship of alcohol use and subsequent self-reported health status among people with HIV
por: Pytell, Jarratt D., et al.
Publicado: (2023)

Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice
por: Pytell, Jarratt D., et al.
Publicado: (2019)

Individual and social network correlates of responding to multiple overdoses among a cohort of people who use drugs
por: Wagner, Karla D., et al.
Publicado: (2022)

A qualitative study examining the benefits and challenges of incorporating patient-reported outcome substance use and mental health questionnaires into clinical practice to improve outcomes on the HIV care continuum
por: Monroe, Anne K., et al.
Publicado: (2018)

2497. Analysis of Social Determinants of Health (SDOH) and their Implications for Hepatitis C Treatment in People Who Inject Drugs: The Case of Baltimore
por: Corro, Luis A Gonzalez, et al.
Publicado: (2023)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

2505. Using an Electronic Medical Record Alert to Screen Inpatient Encounters for People with Hepatitis C
por: Pryal, Patrick, et al.
Publicado: (2023)

4131 Recruitment and Retention of Individuals with a Cocaine Use Disorder
por: Brown, Kate, et al.
Publicado: (2020)

1590 Hepatitis C Care among HIV Infected Patients in a Community Based Clinic
por: Grier, Brittany, et al.
Publicado: (2014)

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
por: Frost, Madeline C., et al.
Publicado: (2022)

Perceptions, knowledge, and communication preferences about indoor mold and its health implications among persons affected by Hurricane Harvey: a focus group analysis
por: Gandhi, Pooja, et al.
Publicado: (2022)

Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting
por: Sweeney, Mary M., et al.
Publicado: (2022)

A longitudinal study of vaccine hesitancy attitudes and social influence as predictors of COVID-19 vaccine uptake in the US
por: Latkin, Carl, et al.
Publicado: (2022)

An unusual cause of fever in a patient with common variable immunodeficiency
por: Dang, Andrew T., et al.
Publicado: (2017)

Benefits of using intrathecal buprenorphine
por: Rabiee, Seyed Mozaffar, et al.
Publicado: (2014)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML
por: Jones, LaQuita, et al.
Publicado: (2021)

1291 Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to Care
por: Falade-Nwulia, Oluwaseun, et al.
Publicado: (2014)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Behavioral and Attitudinal Correlates of Trusted Sources of COVID-19 Vaccine Information in the US
por: Latkin, Carl A., et al.
Publicado: (2021)

Practical Considerations for the Clinical Use of Buprenorphine
por: Jones, Hendrée E.
Publicado: (2004)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
por: Blazes, Christopher K., et al.
Publicado: (2020)

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
por: Tardelli, Vitor, et al.
Publicado: (2023)

Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder
por: Berry, Amanda R. W., et al.
Publicado: (2021)

Evaluating sensitivity and specificity of the Biomeme Franklin™ three9 real-time PCR device and SARS-CoV-2 go-strips assay using clinical samples
por: Voelker, Chet R., et al.
Publicado: (2022)

Use of Cocaine
Publicado: (1894)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Buprenorphine
por: Mazurek, Jaroslaw, et al.
Publicado: (2014)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD
por: Dayton, Lauren, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_30sggo6gnvpsn79pslfn82ka8r